Latest news
Loading news…
89bio is a biopharmaceutical company that develops clinical-stage therapies for liver and cardiometabolic diseases.
89bio on Acquirezy — acquisitions, funding rounds, investments, investors, key people & contacts.
89bio was acquired by Roche in 2025 for $2.4B.
Total Funding
$1.18B
Funding Rounds
9
Last Funding
Acquisitions
0
Monthly Visits
Contacts
62
About 89bio
Funding & Financials
- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- San Francisco, California, United States
89bio Funding Rounds
9 results
Upgrade to Pro to view this datasetUpgrade
| Organization Name | Funding Type | Lead Investor Names | Org Hq Country | ||
|---|---|---|---|---|---|
1–5 of 9Show
Page 1 / 2
89bio Key People
Chief Financial Officer
Chief Technical Operations Officer and Head of Quality
CEO
Chief Medical Officer
Chief Operating Officer and Chief Business Officer
62
professional contacts at 89bio
Contact execs at 89bio →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Bulk Dataset Export
Need the data in bulk? Buy the entire dataset.
5.4M company profiles200K+ acquisitions700K+ funding rounds327K investors2M+ people61M contacts45K schools
Delivered as CSV, JSON or Parquet — at startup-friendly pricing.
FAQs about 89bio
People who checked this page also checked these
Browse the full Acquirezy directory.